For people with mild-to-moderate Graves’ eye disease in areas where selenium levels are normal, taking 200 micrograms of selenium daily with B vitamins for six months may lead to a modest improvement in quality of life compared to taking B vitamins alone.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review and meta-analysis of multiple double-blind RCTs in selenium-sufficient populations would establish whether selenium supplementation consistently improves quality of life in Graves’ ophthalmopathy, accounting for heterogeneity in dosing, duration, and outcome measures.
A systematic review and meta-analysis of all double-blind, placebo-controlled RCTs evaluating selenium supplementation (100–200 μg/day) in adults with mild-to-moderate Graves’ ophthalmopathy in selenium-sufficient regions, using GO-QOL as the primary outcome, with follow-up of at least six months. Studies must report mean change, standard deviation, and sample size. Subgroup analyses by baseline selenium status, disease severity, and concomitant therapies must be included.
A double-blind RCT would determine whether selenium supplementation causes a clinically meaningful improvement in quality of life in Graves’ ophthalmopathy, independent of participant or assessor expectations.
A multicenter, double-blind, placebo-controlled RCT of 300 adults aged 18–65 with mild-to-moderate Graves’ ophthalmopathy and confirmed selenium sufficiency (plasma selenium >120 μg/L), randomized to receive 100 μg sodium selenite twice daily or identical placebo, alongside standardized vitamin B complex, for six months. Primary outcome: mean change in GO-QOL score from baseline to six months, assessed by blinded ophthalmologists and independent raters.
A prospective cohort study could determine whether selenium supplementation is associated with sustained quality of life improvements over time in real-world settings, accounting for adherence and confounding factors.
A prospective cohort study following 500 adults with mild-to-moderate Graves’ ophthalmopathy in selenium-sufficient regions for two years, comparing those who choose to take selenium (100–200 μg/day) with those who do not, measuring GO-QOL, CAS, and thyroid antibody titers at baseline, 6, 12, and 24 months, adjusting for age, sex, smoking, thyroid function, and concomitant treatments.
A case-control study could identify whether patients with minimal quality of life improvement after selenium supplementation differ in baseline characteristics from those with marked improvement.
A case-control study comparing 100 patients with mild-to-moderate Graves’ ophthalmopathy who received selenium and showed no improvement in GO-QOL (cases) to 100 matched patients who showed ≥6-point improvement (controls), analyzing baseline selenium levels, genetic polymorphisms in selenoproteins, smoking status, and thyroid antibody titers.
A cross-sectional study could identify whether selenium levels correlate with baseline quality of life scores in Graves’ ophthalmopathy patients, but cannot determine if supplementation changes outcomes.
A cross-sectional survey of 500 adults with mild-to-moderate Graves’ ophthalmopathy in selenium-sufficient regions, measuring plasma selenium concentration and GO-QOL score at a single time point, adjusting for age, sex, smoking, and thyroid autoantibody levels.